The homogeneity of our cohort—characterized by a consistent diagnosis of IDH-wildtype GBM per WHO 2021 criteria and standardized postoperative treatment—enhances the internal validity of our findings, thereby reducing selection bias. This evidence concerns the gene IDH2 and glioblastoma.